ALBHF (Alibaba Health Information Technology) Growth Rank: 7 (As of Sep. 03, 2026) — 13% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ALBHF Alibaba Health Information Technology Ltd ALBHF
51 GF Score
Price $0.40
GF Value $0.70
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Alibaba Health Information Technology Growth Rank?

Alibaba Health Information Technology ALBHF 51 Growth Rank is 7 as of Sep. 03, 2026, which is 13% below its 10-year median of 8.00. GuruFocus rates ALBHF with a GF Score™ of 51/100 and a GF Value™ of $0.70 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Alibaba Health Information Technology has the Growth Rank of 7.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Alibaba Health Information Technology Growth Rank Related Terms

Alibaba Health Information Technology Growth Rank Competitor Comparison

For the Pharmaceutical Retailers subindustry, Alibaba Health Information Technology's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alibaba Health Information Technology Growth Rank vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Alibaba Health Information Technology's Growth Rank distribution charts can be found below:

* The bar in red indicates where Alibaba Health Information Technology's Growth Rank falls into.


ALBHF
51GF Score
Alibaba Health Information Technology Ltd ALBHF
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 7 mean?
Alibaba Health Information Technology (ALBHF) has a Growth Rank of 7 as of Sep. 03, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Alibaba Health Information Technology and its competitors. This is 13% below median its historical median of 8.00. Over the past decade, Alibaba Health Information Technology's Growth Rank has ranged from 3.00 to 10.00.
Is Alibaba Health Information Technology's Growth Rank too high?
Alibaba Health Information Technology's current Growth Rank of 7 is 13% below median its 10-year median of 8.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 10.00. Overall, Alibaba Health Information Technology has a GF Score™ of 51/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alibaba Health Information Technology's Growth Rank compare to competitors?
Alibaba Health Information Technology's Growth Rank of 7 can be compared against companies in the Healthcare Providers & Services industry. Historically, Alibaba Health Information Technology's own Growth Rank has ranged from 3.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Healthcare Providers & Services company?
A good Growth Rank depends on the Healthcare Providers & Services industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Alibaba Health Information Technology and its competitors. Alibaba Health Information Technology's current Growth Rank is 7, which is 13% below median its own 10-year median of 8.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alibaba Health Information Technology stock overvalued right now?
Based on GuruFocus' analysis, Alibaba Health Information Technology (ALBHF) is currently considered Significantly Undervalued. The stock's GF Value™ is $0.70, compared to a current price of $0.40 — trading 43.5% below its estimated fair value. The current Growth Rank is 7, which is 13% below median its 10-year median of 8.00. Alibaba Health Information Technology's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Alibaba Health Information Technology (ALBHF), the current Growth Rank is 7 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alibaba Health Information Technology (ALBHF) Overvalued in 2026?

Based on GuruFocus' analysis, Alibaba Health Information Technology stock appears to be undervalued. The current stock price of $0.40 is trading 43.5% below its estimated GF Value™ of $0.70. GuruFocus considers Alibaba Health Information Technology to be Significantly Undervalued.

Key valuation signals for ALBHF:

  • Growth Rank: 7 (13% below median its 10-year median of 8.00)
  • GF Value™: $0.70 vs. price of $0.40 (43.5% below fair value)
  • GF Score™: 51/100 with 3 warning signs

No single metric tells the full story. See the ALBHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alibaba Health Information Technology Business Description

Address Wangjing East Park, 30th Floor, Greenland Center, Building 9, Zone 4, Chaoyang District, Beijing, CHN
Alibaba Health is of one of China's leading e-commerce platform specializing in healthcare-related products, including prescription drugs, OTC drugs, traditional Chinese medicine, health foods, and so on. The company operates both a third-party B2C service, or 3P, and its own direct-to-consumer business, or 1P, with its own inventory, which can both be accessed by Alibaba's Tmall app and Alipay. The company also provides online consultation services in a separate app although its e-commerce businesses remain its core competency in the long-term. E-commerce accounted for 93% of revenue in fiscal year 2022. We estimate that AliHealth holds about 45% of market share in the industry in terms of GMV. AliHealth is 63.74% owned by its parent company, Alibaba Group.
51GF Score

Get the complete analysis for ALBHF

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.40
Price
$0.70
GF Value